Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Merck, GE Healthcare Collaborate For BACE Inhibitor Development Program

Merck (MRK: Quote), known as MSD outside the U.S. and Canada, and GE Healthcare, an unit of General Electric Co. (GE: Quote), announced a study collaboration, license and supply agreement for use of [18F]Flutemetamol, an investigational positron emission tomography or PET imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme or BACE inhibitor and Merck's lead investigational candidate for Alzheimer's disease.

According to the agreement, GE Healthcare would supply [18F]Flutemetamol to help select patients for trials and assess this investigational agent as a companion diagnostic tool. A joint Merck and GE Healthcare Imaging Advisory Committee would oversee the planned imaging studies.

"In clinical trials, [18F]Flutemetamol demonstrated consistent performance in the visual detection of beta amyloid in the brain when compared with histopathology data," according to Jonathan Allis, general manager, PET, GE Healthcare Medical Diagnostics.

Click here to receive FREE breaking news email alerts for Merck & Co Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
While buying interest has remained somewhat subdued, stocks are seeing modest strength in mid-day trading on Thursday. The slim gains on the day have lifted the S&P 500 to a new record intraday high above the 1,990 level. New home sales in the U.S. showed a notable decrease in the month of June, according to a report released by the Commerce Department on Thursday, with the steep drop offsetting the jump seen in the previous month. After reporting a modest drop in first-time claims for U.S. unemployment benefits in the previous week, the Labor Department released a report on Thursday showing that initial jobless claims unexpectedly fell to their lowest level in over eight years in the week ended July 19th.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.